The SRS summit indicates further room for robotic surgery penetration to rise, but Intuitive faces competition and pressure from remanufactured consumables

Overview

This report summarizes the key information from the Society of Robotic Surgery investor summit and the SRS member physician survey, focusing on product progress, competitive dynamics, ASC channel migration, AI applications, and the impact of remanufactured instruments in robotic surgery across Intuitive Surgical, J&J, Medtronic, and Stryker. The featured company is Intuitive Surgical, with a disclosed price of USD 340.69 as of July 22, 2026, and a target price of USD 324.00.

Core views

The robotic surgery industry remains in a stage of low penetration and continued expansion, with global soft-tissue robotic surgery TAM penetration still in the single digits. Intuitive's da Vinci still holds an overwhelming installed-base advantage globally and in the U.S., and is expected to remain the leader over the next five years; however, the competitive landscape will become more complex. J&J Ottava's FDA approval, Medtronic Hugo's indication expansion, Stryker's focus on soft-tissue robotics and remanufactured da Vinci instruments could all gradually weaken Intuitive's share and the resilience of its I&A business.

Analysis framework

The report is primarily based on management discussions at the SRS investor summit, KOL panel discussions, and a survey of 451 SRS member physicians across different specialties worldwide, analyzing robotic surgery penetration, installed-base share, migration of surgical settings, AI applications, and differences among competing platforms.

Methodology notes

• industry_surveySRS physician survey

  Physician survey and penetration-rate forecasts

  The report uses a survey of 451 SRS member physicians to estimate current and five-year future robot-assisted surgery penetration, platform installed-base share, and ASC surgery migration trends. The sample has selection bias because SRS members have higher technology adoption rates than the overall market, so the report notes that the survey may underestimate the broader market's growth potential.

• competitive_analysisinstalled base share analysis

  Competitive landscape of installed-base share

  The report assesses competitive intensity using current and expected installed-base share for platforms such as da Vinci, Hugo, and Ottava, and distinguishes differences in market maturity between the global and U.S. markets.

• market_structuresite-of-care migration

  Migration of surgical settings toward ASCs

  The report focuses on how the migration of lower-complexity soft-tissue procedures from acute-care hospitals to ASCs affects platform pricing, instrument costs, system footprint, and customer procurement models.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Intuitive Surgical (ISRG.OQ)

  Featured company; the da Vinci platform is the core asset

  Strengths

  Leading installed-base share globally and in the U.S., strong hospital customer base, and dV5 upgrades plus XiR entry into ASCs should help extend the platform ecosystem.

  Weaknesses

  U.S. market penetration is already relatively high, so growth is more moderate than in international markets; the I&A business may be affected by remanufactured instruments and pricing-reduction strategies.

  Comparison

  Compared with J&J Ottava and Medtronic Hugo, da Vinci remains in a leading position; however, competitors are strengthening through existing surgical instrument channels and differentiated designs.

  Risks

  Rapid approval of J&J Ottava, expansion of Medtronic Hugo indications, Stryker potentially entering soft-tissue robotics through acquisition, and remanufactured instruments impacting I&A revenue.

• J&J Ottava

  A newly entering competing platform in soft-tissue robotic surgery

  Strengths

  Received U.S. FDA approval, has a 30%-50% smaller operating-room footprint, and J&J has a strong channel foundation in surgical instruments.

  Weaknesses

  Entered later than Intuitive, initial approved indications are limited, and the international expansion timeline has not been disclosed.

  Comparison

  Relative to da Vinci, it has advantages in footprint and potential ASC fit, but it still needs to build clinical use and installed-base foundations.

  Risks

  There is uncertainty around commercialization pace, speed of indication expansion, physician adoption, and hospital budgets.

• Medtronic Hugo

  Competing platform in soft-tissue robotic surgery

  Strengths

  Modularity, an open display console, LigaSure instruments, the Touch Surgery digital ecosystem, and a customer partnership model create differentiation.

  Weaknesses

  In the U.S., approvals are still currently limited to urology, and installed-base disclosure is limited.

  Comparison

  If it obtains general surgery and gynecology indications, it could cover about 80% of the soft-tissue robotic surgery market.

  Risks

  The pace of U.S. indication approvals and hospital adoption could affect its catch-up ability.

• Stryker Mako

  Orthopedic robotics platform, and may indirectly affect competition in soft-tissue robotics

  Strengths

  About 70% of U.S. knee reconstruction and about 50% globally use Mako, and there is still room for growth in international markets.

  Weaknesses

  It has not yet entered soft-tissue robotics, and if it does, it is expected to do so through acquisition.

  Comparison

  Mako has already proven platform value in orthopedic robotics, but it is not a direct peer to da Vinci in soft-tissue robotics.

  Risks

  If Stryker acquires a soft-tissue robotics company or enters the remanufactured da Vinci instrument market, it would create significant competitive pressure on Intuitive.

Key data

• Global robot-assisted surgery penetration33% currently to 48% in five yearsSRS physician survey average, implying approximately +11% CAGR in global robotic procedure volume.
• U.S. robot-assisted surgery penetration64% currently to 69% in five yearsThe U.S. market is more mature, with incremental growth mainly coming from conversion of open surgery to robotic surgery.
• da Vinci global installed-base share81% currently to 68% in five yearsShare is expected to decline but still remain in the lead.
• da Vinci U.S. installed-base share98% currently to 84% in five yearsEven as competitors enter, the U.S. market is still expected to remain dominant.
• Medtronic Hugo share in five years10%Survey respondents expect Medtronic to become the second-largest global player.
• ASC procedure mix forecastroughly one-third of addressable surgeries in five yearsThis has important implications for lower-complexity soft-tissue procedures and robotic platform business models.
• Intuitive Surgical recent priceUSD 340.69As of July 22, 2026.
• Deutsche Bank target priceUSD 324.00The rating disclosure table shows the current rating is Sell.

Impact & implications

At the industry level, rising robotic surgery penetration should continue to support overall market expansion, while new competitors may also broaden market education and hospital willingness to procure. At the company level, Intuitive still has advantages in platform, installed base, and customer relationships, but its high share means future share decline, I&A pricing pressure, ASC cost sensitivity, and substitution risk from remanufactured instruments will all become key constraints on valuation and earnings flexibility.

Risks

• The commercialization pace of J&J Ottava after FDA approval may be faster than expected, putting pressure on Intuitive's future installed-base share.
• If Medtronic Hugo obtains general surgery and gynecology indications, it will expand its addressable market and increase hospital willingness to evaluate alternative platforms.
• The ASC channel is more sensitive to pricing and per-procedure costs, which could weaken Intuitive's pricing power for systems and its I&A business.
• If adoption of remanufactured da Vinci instruments rises, the impact on Intuitive's I&A revenue could be greater than the company suggests.
• The SRS survey sample is skewed toward physicians with higher technology adoption rates, which may differ from the actual adoption pace of the broader market.
• Regulatory approvals for robotic surgery platforms, indication expansion, hospital capital spending cycles, and the pace of clinical adoption could all affect industry growth.

What to watch

• The pace of follow-on indication approvals for J&J Ottava, especially expansions in urology, gynecology, and general surgery such as hernia repair.
• Installation and usage trends for Intuitive dV5 upgrades and XiR in the ASC channel.
• Whether the second round of EUP launches in 2027 can reduce I&A cost per procedure for high-volume, low-complexity surgeries and improve adoption.
• Adoption of remanufactured da Vinci instruments, and whether Stryker enters the related market.
• Medtronic Hugo's progress in U.S. general surgery and gynecology approvals and its international installed-base disclosure.
• Whether the penetration gap between the U.S. and international robotic surgery markets continues to widen.